First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases

PURPOSE: PI3Ks are potential therapeutic targets in immune-inflammatory diseases. These studies aimed to investigate the safety, tolerability and PK profile of seletalisib, a selective inhibitor of PI3Kδ in humans. METHODS: These phase I, randomised, double-blind, placebo-controlled, single-centre s...

Descripción completa

Detalles Bibliográficos
Autores principales: Helmer, Eric, Watling, Mark, Jones, Emma, Tytgat, Dominique, Jones, Mark, Allen, Rodger, Payne, Andrew, Koch, Annelize, Healy, Eugene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Pharmacokinetics and Disposition
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384962/
https://www.ncbi.nlm.nih.gov/pubmed/28160012
http://dx.doi.org/10.1007/s00228-017-2205-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384962/
https://www.ncbi.nlm.nih.gov/pubmed/28160012
http://dx.doi.org/10.1007/s00228-017-2205-7

Ejemplares similares